Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

NEOGEN CORP

NEOG · Nasdaq · CIK 0000711377 · Healthcare · Medical Devices

INSIDER SIGNAL

40.4 / 100

1 buyers · 2 purchase transaction lines · $10.4K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleModerate
RecencyStrong
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+1.8 / 25
Role+13.0 / 20
Recency+8.6 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: CEO (CEO, chair and 10% owners score lowest)
  • ✓ Recent activity · latest purchase 2026-10-09

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Moylan John PatrickChief Accounting Officer
○○○○○
Nassif MikhealCEO
●○○●
Stacey Jennifer EvansChief Legal Officer
○○
Rocklin Amy MFormer Chief Legal Officer
○○
Wainer Andrea FDirector
○
RODRIGUEZ RAFAEL ADirector
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 8 additional owner(s) remain in Form 4 evidence.

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Nassif Mikheal · $10.4K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-08-04–2026-08-04

Roles in the peak window: CEO. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

40.4 / 100

Latest recorded score

↓ -0.3 ptsversus the previous recorded snapshot
  1. 41.1
  2. 41.0
  3. 40.8
  4. 40.7
  5. 40.4

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

7Purchases
0Sales
53Other Form 4 lines
52SEC filings · 365 days
BUYING2 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER21 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-2.2%
3M
+19.5%
6M
+32.8%
12M
+107.6%

Volatility & liquidity

Volatility
62.0%
Beta
—
Avg daily value
USD 39.2M

Valuation

Market cap
USD 2.7B
P/E
—

Fundamentals

Profit margin
-0.9%
ROE
-0.4%
Industry
Medical Devices

Market data

Price data up to: 2026-10-15 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2026-05-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
11,846,307
Previous report
11,168,684
Avg daily volume
5,825,645
Days to cover
2.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-09Nassif MikhealPurchase (P)Common Stock505USD 11.95USD 6,035SEC filing ↗
2026-08-04Nassif MikhealPurchase (P)Common Stock370USD 11.81USD 4,370SEC filing ↗
2026-02-17Nassif MikhealPurchase (P)Common Stock23USD 10.94USD 252SEC filing ↗
2026-02-02Nassif MikhealPurchase (P)Common Stock24USD 10.00USD 240SEC filing ↗
2026-01-26Nassif MikhealPurchase (P)Common Stock25USD 9.86USD 246SEC filing ↗
2026-01-16Nassif MikhealPurchase (P)Common Shares137USD 9.33USD 1,278SEC filing ↗
2025-11-03Nassif MikhealPurchase (P)Common Shares177USD 6.25USD 1,106SEC filing ↗
2025-05-12Gupta AashimaPurchase (P)Common Stock16,000USD 6.25USD 100,000SEC filing ↗
2025-04-25Woteki Catherine EPurchase (P)Common Stock5,770USD 5.17USD 29,831SEC filing ↗
2025-04-24BOREL JAMES CPurchase (P)Common Stock30,000USD 4.99USD 149,700SEC filing ↗
2025-04-24BOREL JAMES CPurchase (P)Common Stock35,000USD 4.89USD 171,150SEC filing ↗
2025-04-24BOEHM WILLIAM TPurchase (P)Common Stock5,000USD 5.24USD 26,200SEC filing ↗
2025-04-23Rocklin Amy MPurchase (P)Common Stock12,500USD 4.99USD 62,375SEC filing ↗
2025-04-22Tobin James PPurchase (P)Common Stock10,000USD 4.73USD 47,300SEC filing ↗
2025-04-22RODRIGUEZ RAFAEL APurchase (P)Common Stock7,474USD 4.59USD 34,306SEC filing ↗

Form 4 evidence

60 transaction lines in the latest 365-day window; 340 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-09Nassif MikhealPurchase (P)Common Stock505USD 11.95USD 6,035SEC filing ↗
2026-10-01Woteki Catherine EAward / grant (A)Restricted Stock Units9,804USD 12.24USD 120,001SEC filing ↗
2026-10-01Wainer Andrea FAward / grant (A)Restricted Stock Units9,804USD 12.24USD 120,001SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-09Nassif MikhealPurchase (P)Common Stock505USD 11.95USD 6,035SEC filing ↗
2026-10-01Woteki Catherine EAward / grant (A)Restricted Stock Units9,804USD 12.24USD 120,001SEC filing ↗
2026-10-01Wainer Andrea FAward / grant (A)Restricted Stock Units9,804USD 12.24USD 120,001SEC filing ↗
2026-10-01RODRIGUEZ RAFAEL AAward / grant (A)Restricted Stock Units9,804USD 12.24USD 120,001SEC filing ↗
2026-10-01Pelossof AviAward / grant (A)Restricted Stock Units9,804USD 12.24USD 120,001SEC filing ↗
2026-10-01Gupta AashimaAward / grant (A)Restricted Stock Units9,804USD 12.24USD 120,001SEC filing ↗
2026-10-01Green Ronald DAward / grant (A)Restricted Stock Units9,804USD 12.24USD 120,001SEC filing ↗
2026-10-01CAPELLO JEFFREY DAward / grant (A)Restricted Stock Units9,804USD 12.24USD 120,001SEC filing ↗
2026-10-01BOREL JAMES CAward / grant (A)Restricted Stock Units9,804USD 12.24USD 120,001SEC filing ↗
2026-08-19Nassif MikhealTax withholding (F)Restricted Stock Units20,397USD 11.87USD 242,112SEC filing ↗
2026-08-19Moylan John PatrickTax withholding (F)Restricted Stock Units2,365USD 11.87USD 28,073SEC filing ↗
2026-08-14Stacey Jennifer EvansAward / grant (A)Common Stock38,627USD 11.65USD 450,005SEC filing ↗
2026-08-14Riggsbee Richard BryanAward / grant (A)Common Stock51,502USD 11.65USD 599,998SEC filing ↗
2026-08-14Ranalli Tamara A.Award / grant (A)Common Stock25,751USD 11.65USD 299,999SEC filing ↗
2026-08-14Nassif MikhealAward / grant (A)Common Stock141,631USD 11.65USD 1,650,001SEC filing ↗
2026-08-14Moylan John PatrickAward / grant (A)Restricted Stock Units8,584USD 11.65USD 100,004SEC filing ↗
2026-08-04Nassif MikhealPurchase (P)Common Stock370USD 11.81USD 4,370SEC filing ↗
2026-06-03Moylan John PatrickTax withholding (F)Restricted Stock Units2,553USD 8.75USD 22,339SEC filing ↗
2026-05-18Rocklin Amy MOption exercise / conversion (M)Common Stock35,183USD 9.29USD 326,850SEC filing ↗
2026-05-18Rocklin Amy MTax withholding (F)Common Stock10,241USD 9.29USD 95,139SEC filing ↗
2026-05-04Moylan John PatrickOption exercise / conversion (M)Common Stock4,558USD 9.53USD 43,438SEC filing ↗
2026-05-04Moylan John PatrickTax withholding (F)Common Stock1,568USD 9.53USD 14,943SEC filing ↗
2026-05-01Stacey Jennifer EvansAward / grant (A)Common Stock39,349USD 9.53USD 374,996SEC filing ↗
2026-02-17Nassif MikhealPurchase (P)Common Stock23USD 10.94USD 252SEC filing ↗
2026-02-02Nassif MikhealPurchase (P)Common Stock24USD 10.00USD 240SEC filing ↗
2026-01-26Nassif MikhealPurchase (P)Common Stock25USD 9.86USD 246SEC filing ↗
2026-01-16Nassif MikhealPurchase (P)Common Shares137USD 9.33USD 1,278SEC filing ↗
2026-01-07Ranalli Tamara A.Award / grant (A)Common Stock50,813USD 7.38USD 375,000SEC filing ↗
2026-01-07Ranalli Tamara A.Award / grant (A)Common Stock50,813USD 7.38USD 375,000SEC filing ↗
2025-12-01Naemura David H.Option exercise / conversion (M)Common Stock12,912USD 5.98USD 77,214SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerNEOG
CIK0000711377
SectorHealthcare
IndustryMedical Devices Yahoo Finance
SEC SIC2835 In Vitro & In Vivo Diagnostic Substances
ExchangeNasdaq

Data coverage

Local Form 4 history340 transaction lines from 2020-01-06 to 2026-10-09
44 P purchase lines · 58 S sale lines · 238 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.